Clinical Trials Browser

Terminated × ibrutinib × Plasma cell × Clear all

NCT03015792 2025-08-17

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Phase 1 Terminated

Multiple Myeloma

NCT02943473 2020-12-16

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Phase 2 Terminated

9 enrolled 6 charts

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT02548962 2019-11-21

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 12 charts

Multiple Myeloma

NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma